POPULARITY
Categories
63 episodes with inhibitors
53 episodes with inhibitors
53 episodes with inhibitors
32 episodes with inhibitors
45 episodes with inhibitors
45 episodes with inhibitors
63 episodes with inhibitors
28 episodes with inhibitors
22 episodes with inhibitors
22 episodes with inhibitors
26 episodes with inhibitors
23 episodes with inhibitors
11 episodes with inhibitors
26 episodes with inhibitors
19 episodes with inhibitors
26 episodes with inhibitors
14 episodes with inhibitors
20 episodes with inhibitors
25 episodes with inhibitors
30 episodes with inhibitors
18 episodes with inhibitors
10 episodes with inhibitors
10 episodes with inhibitors
13 episodes with inhibitors
29 episodes with inhibitors
19 episodes with inhibitors
22 episodes with inhibitors
17 episodes with inhibitors
8 episodes with inhibitors
10 episodes with inhibitors
9 episodes with inhibitors
12 episodes with inhibitors
12 episodes with inhibitors
18 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
13 episodes with inhibitors
25 episodes with inhibitors
7 episodes with inhibitors
17 episodes with inhibitors
3 episodes with inhibitors
10 episodes with inhibitors
6 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
4 episodes with inhibitors
7 episodes with inhibitors
7 episodes with inhibitors
6 episodes with inhibitors
6 episodes with inhibitors
9 episodes with inhibitors
3 episodes with inhibitors
6 episodes with inhibitors
“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.
A large observational study found small but potentially meaningful differences in cardiovascular safety among sulfonylureas compared to DPP-4 inhibitors in type 2 diabetes, with glipizide showing a statistically higher risk of MACE. A separate study revealed that over half of advanced-stage lung and colorectal cancer cases involved missed diagnostic opportunities, highlighting systemic delays in workups and follow-up. Finally, the EchoNext deep learning model accurately predicted structural heart disease from ECG data alone, outperforming cardiologists and showing potential for scalable, cost-effective screening. These findings underscore the importance of individualized treatment, earlier cancer detection, and AI-enabled cardiac diagnostics.
The Peptique is LIVE! Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products.Have questions? Feel free to reach out to me: tarawest@westwellnessatx.comWant to get started the right way, but don't know where to start. Email me tarawest@westwellnessatx.com to set up a 30 minute $100 session to get your personalized protocol. A special discount on your first order will be included. These spots fill up fast so schedule today!Want the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over!Follow me on instagram @westwellnessatxTakeaways: This podcast episode marks the 50th installment, showcasing significant growth and listener engagement. The primary focus of today's discussion centers on the relationship between NAD and cancer risk. NAD is crucial for cellular functions including energy production, DNA repair, and immune response. Current research presents mixed results regarding NAD's role in cancer, demanding further investigation and caution. NAD supplementation may not inherently cause cancer but could influence existing cancer cell behavior. Listeners are encouraged to conduct their own research and consider their personal health situations regarding NAD usage. Research Links NAD+ biology, aging, immunity, DNA repairCovarrubias et al. “NAD+ metabolism and its roles in cellular processes during ageing” (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/ PMCGhanem et al. “Inhibitors of NAD+ Production in Cancer Treatment” (NAMPT/NAPRT review). https://pmc.ncbi.nlm.nih.gov/articles/PMC10889166/ PMCManickam et al. “Nampt: a new therapeutic target for modulating NAD metabolism in cancer and inflammation” (2025 review). https://cdnsciencepub.com/doi/10.1139/cjpp-2024-0400 Canadian Science PublishingExtracellular metabolism and cellular uptake (do IVs reach cells?)Gasparrini et al. “Enzymology of extracellular NAD metabolism” (ectoenzymes; NR/NMN/NAM import). https://pmc.ncbi.nlm.nih.gov/articles/PMC8038981/ PMCYusri et al. “The role of NAD+ metabolism and its modulation” (2025 review; NR via ENTs; NMN dephosphorylation; SLC12A8 debate). https://www.nature.com/articles/s44324-025-00067-0 NatureYaku et al. “NR and NMN: similarities and differences” (2025 perspective; NMN→NR conversion before uptake). https://www.science.org/doi/10.1126/sciadv.adr1538 ScienceHuman IV NAD+ / IV NR dataGrant et al. “A Pilot Study… during a 6-hour intravenous infusion of NAD+” (750 mg IV NAD+, plasma/urine...
Send us a textWelcome back Rounds Table Listeners! Today we have a solo episode with Dr. Mike Fralick. This week, he discusses a recently published trial exploring the simultaneous initiation of SGLT2 inhibitors and finerenone (a nonsteroidal mineralocorticoid receptor antagonist) in persons with chronic kidney disease and type 2 diabetes. Here we go!Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (0:00 – 9:28).Calling keen trainees! (9:29 - 10:28)Trainees, med students, residents: The Rounds Table and Trial Files are looking for keen individuals to support our efforts.Trial Files is a free monthly newsletter on practice-changing trials, delivered straight to your inbox (https://trialfiles.substack.com/).Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods
In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.Presenters:Eytan M. Stein, MDChief, Leukemia ServiceDirector, Program for Drug Development in LeukemiaAssociate Attending PhysicianLeukemia Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkEunice S. Wang, MDChief, Leukemia ServiceProfessor of OncologyDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkLink to full program: https://bit.ly/4f4an0O
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trial Presenters:James Davis, PharmD, BCOPClinical Pharmacy Specialist, Malignant HematologyMUSC Hollings Cancer CenterAssistant ProfessorMUSC College of PharmacyCharleston, South CarolinaVictoria Nachar, PharmD, BCOPClinical Pharmacist Specialist, HematologyUniversity of Michigan Rogel Cancer CenterAnn Arbor, MichiganLink to full program: https://bit.ly/3H2EcSX
In this week's episode we'll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.Featured Articles:Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in ChinaNovel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse modelClinical phenotype and pathophysiological mechanisms underlying qualitative low VWF
In this episode, Dr. William Gradishar reviews key data on PARP inhibitors in breast cancer, including early insights from the OPERETTA and CompLEEment trials. He explores emerging combination strategies with immunotherapy and DNA-damaging agents, the potential to reduce chemotherapy use, and new tools to better identify candidates for targeted treatment. Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!
“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35
Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.
Dom talks with George Reeves, Commercial Director at Ruminant Biotech, about winning the Prototype category at the recent Fieldays Innovation Awards for its slow-release bolus 'Emitless', which delivers over 75% methane reduction in cattle for 100 days from a single treatment, how it works and the possibility for farmers to be financially rewarded for using the product and other methane inhibitors in the future. Tune in daily for the latest and greatest REX rural content on your favourite streaming platform, visit rexonline.co.nz and follow us on Instagram, Facebook and LinkedIn for more.
On this episode of Translating Proteomics, Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover:Needs in plasma proteomicsHow proteomics impacts drug development – with special guest Don Kirkpatrick Ph.D.!How lifestyle impacts the proteomeHow the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer's disease researchReferencesShome et al., 2022 - Serum autoantibodyome reveals that healthy individuals share common autoantibodieshttps://www.sciencedirect.com/science/article/pii/S2211124722006489LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health.Sylman et al., 2018 - A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patientshttps://www.nature.com/articles/s41598-018-25019-1Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology.Krönke et al., 2014 - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellshttps://www.science.org/doi/10.1126/science.1244851Seminal paper describing selective protein degradation caused by lenalidomide.Fink and Ebert 2015 - The novel mechanism of lenalidomide activityhttps://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activityReview of research elucidating the mechanisms of lenalidomide activityNdoja et al., 2025 - COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathwayhttps://www.mdpi.com/2073-4409/14/13/975Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradationSong et al., 2022 - RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacyhttps://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3KUse proteomics to discover that inavolisib acts through selective degradation of mutant PI3KαCanon et al., 2019 - The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityhttps://www.nature.com/articles/s41586-019-1694-1Covers the development of an inhibitor of KRAS mutant KRAS (G12C).Schneider et al., 2024 - Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axishttps://www.nature.com/articles/s42255-024-01108-6Review on the gut-brain axisWebpage for Johanna Lampe's Lab at Fred Hutch Cancer Center
We talk with Abdullahi Jamiu, a graduate student at the Virginia Polytechnic Institute and State University in Blacksburg, VA, who studies how encephalitic alphaviruses modulate cellular transcription and antiviral responses to discover novel therapeutic targets.
UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]
UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]
UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]
UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient's cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NVF865. CME credit will be available until June 29, 2026.Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.
Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.
In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:Patient candidacy considerationsTreatment advancement strategies that go beyond topical therapiesThe importance of patient-centered care that address patients' fears and needsA detailed patient case to highlight take home pointsPresenterDaniel C. Butler, MDAssistant Dean Student AffairsUniversity of Arizona College of Medicine – TucsonTucson, ArizonaShawn G. Kwatra, MDDr. Joseph W. Burnett Endowed Professor and Chair Department of DermatologyUniversity of Maryland School of MedicineBaltimore, MarylandProgram page:https://bit.ly/4kTP04D
In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:The available biologic therapies that specifically target IL-13Where these agents fall in the 2024 American Academy of Dermatology treatment algorithmHow these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitorsA detailed patient case to highlight take home pointsPresenterAndrew F. Alexis, MD, MPHProfessor of Clinical DermatologyWeill Cornell Medical College New York, New YorkDaniel C. Butler, MDAssistant Dean Student AffairsUniversity of Arizona College of Medicine – TucsonTucson, ArizonaShawn G. Kwatra, MDDr. Joseph W. Burnett Endowed Professor and Chair Department of DermatologyUniversity of Maryland School of MedicineBaltimore, MarylandProgram page:https://bit.ly/4kTP04D
Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inhibitors for Axial Spondyloarthritis New IL-17 Inhibition New Molecular Constructs
In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9
Watch Here : https://www.youtube.com/watch?v=eI1Y7IFENIo Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve
In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.
Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications
Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12
Can we do more than prescribe pills to address men's sexual health complaints? In this episode of the BackTable Urology Podcast, men's health expert Dr. Mohit Khera from Baylor College of Medicine joins guest host Dr. Amy Pearlman for a deep dive into testosterone management and the full spectrum of erectile dysfunction therapies. --- SYNPOSIS The conversation covers daily tadalafil use, lifestyle optimization, and the nuanced role of off-label medications. Dr. Khera also highlights emerging technologies like the Tech Ring and radiofrequency treatments, alongside practical insights into semen analysis and hormonal health markers. Throughout, he emphasizes a holistic, patient-centered approach to sexual health—blending medical therapy with meaningful lifestyle change. This is a must-listen for general urologists, men's health specialists, and trainees looking to expand their toolkit in this evolving field. --- TIMESTAMPS 00:00 - Introduction02:13 - Erectile Dysfunction and Testosterone08:05 - Young Men's Health and Early Detection10:20 - Semen Analysis for Overall Health12:50 - Daily Tadalafil and Its Benefits16:40 - Proactive Sexual Health Management21:28 - Female Sexual Health25:16 - Treating Delayed Ejaculation28:53 - Psychogenic Erectile Dysfunction31:16 - Technology in Sexual Health35:54 - Lifestyle Modifications for Better Sexual Health41:55 - Resources and Referrals for Patients44:30 - Final Thoughts
Dr. Grant Tinsley joins the discussion as the body composition expert.Myostatin is a key regulator of muscle growth.Wendy Whippete the most jacked muscled up dogThe concern of GLP-1 receptor agonists and muscle mass loss.Overview of Courage trial looking at semaglutide and trevogrumab and lean mass lossUpcoming Believe trial coming out (bimagrumab and semaglutide)Exercise remains crucial for muscle health and function.MRI data from SURPASS MRI provides new insights into muscle volume changes.The combination of medications may have varying effects on muscle mass.Caution is advised regarding the long-term effects of new drugs.Clinical benefits of medications often outweigh concerns about muscle loss.Future research will explore the synergy between exercise and medication.Other docs who lift podcasts with Dr. Grant:Tirzepatide muscle lossLean mass loss and GLP-1 meds
Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications
SGLT2 Inhibitors Cardiovascular and Safety Outcomes in Chronic Diseases by Citeline
Dr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. CME information and select publications here.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have revolutionized treatment for type 2 diabetes, heart failure, and chronic kidney disease—but they're creating new challenges for anesthesia professionals. With more patients on these medications heading to surgery, understanding their unique perioperative risks has never been more critical.At the heart of this issue lies euglycemic ketoacidosis—a potentially life-threatening complication that's particularly insidious because it lacks the classic hyperglycemia that would normally trigger suspicion. We dive deep into the latest evidence, revealing that patients on SGLT2 inhibitors have an increased risk of developing postoperative ketoacidosis compared to those not taking these medications, with significantly worse outcomes when complications occur.We present a practical algorithm for risk stratification, considering factors like procedure duration, anesthesia type, diabetes control, and comorbidities. You'll learn which patients should hold their medication, which can proceed with caution, and what monitoring strategies to implement when patients haven't properly discontinued their medication before surgery. This guidance is especially valuable for emergency cases where postponement isn't an option.Whether you're developing institutional protocols or making decisions for individual patients, this episode equips you with the knowledge to navigate the complexities of SGLT2 inhibitor management in the perioperative period. Subscribe to stay informed about the latest in anesthesia patient safety and join our mission to ensure no one is harmed by anesthesia care.For show notes & transcript, visit our episode page at apsf.org: https://www.apsf.org/podcast/257-sweet-trouble-perioperative-management-of-sglt2-inhibitors/© 2025, The Anesthesia Patient Safety Foundation
In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: • The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. • Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. • Strategies for managing these side effects to improve patient quality of life and treatment adherence. • Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
In today's episode, supported by SpringWorks Therapeutics, we spoke with Christopher L. Moertel, MD, about the evolution of treatments for neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PN). Dr Moertel is a professor and the Pediatric Neuro-Oncology Fellowship Program director in the Division of Pediatric Hematology/Oncology, a faculty member in the Department of Pediatrics, medical director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs, co-medical director of the Katie Hageboeck Children's Cancer Research Fund Clinic, clinical neuro-oncology leader of the Brain Tumor Program, and the Kenneth and Betty Jayne Dahlberg Professor at the University of Minnesota School of Medicine in Minneapolis. In our exclusive interview, Dr Moertel discussed the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib (Gomekli) and selumetinib (Koselugo); the benefits of offering treatment options in oral formulations; the toxicities associated with MEK inhibitors; the importance of managing these adverse effects to ensure long-term treatment adherence; and the need for continued oncology education to optimize treatment outcomes for this population.
“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21
Drs. VanderPluym and Starling review the updated position statement from the American Headache Society indicating that CGRP-targeting migraine therapies should be considered as a first-line option.
Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications
In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how to address questions related to BTK Inhibitors with patients. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss the clinical trial data available in both the relapsing and progressive cohorts. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
Dr. Justin Abbatemarco talks with Dr. Jiwon Oh about Bruton Tyrosine Kinase (BTK) Inhibitors and the recent data on tolebrutinib in multiple sclerosis. Read the related article on Tolebrutinib versus Teriflunomide in The New England Journal of Medicine. Read the related article on Tolebrutinib in Nonrelapsing Secondary Progressive MS in The New England Journal of Medicine. Disclosures can be found at Neurology.org.
Dr. Keith Baar is a Professor at the University of California, Davis in the Department of Physiology and Membrane Biology. During his Ph.D. studies, his research revealed that mechanical strain on muscle fibers activates the mammalian target of rapamycin (mTOR) signaling pathway, a crucial regulator of muscular hypertrophy. Subsequently, he studied the molecular dynamics of skeletal muscle adaptation to endurance training under the guidance of Dr. John Holloszy, a legend in the field of exercise physiology, considered the father of modern exercise biochemistry. Building on all of this experience, he conducted research into tendon health and the potential for engineering ligaments, which could have implications for treatment and recovery from injuries.Sponsors:Cresset prestigious family office for CEOs, founders, and entrepreneurs: https://cressetcapital.com/tim (book a call today)AG1 all-in-one nutritional supplement: https://DrinkAG1.com/Tim (1-year supply of Vitamin D (and 5 free AG1 travel packs) with your first subscription purchase.)Shopify global commerce platform, providing tools to start, grow, market, and manage a retail business: https://shopify.com/tim (one-dollar-per-month trial period)*Links to everything discussed: https://tim.blog/2025/02/26/dr-keith-baar/Timestamps:[00:00:00] Start [00:07:12] How I discovered Keith's work through a tweet about tennis elbow and rock climbing.[00:07:54] Emil Abrahamsson's hangboard training protocol.[00:09:20] The fundamental principles of strength training and connective tissue adaptation.[00:10:36] mTOR complex 1 and its role in muscle growth.[00:12:06] Engineered ligaments and the discovery of minimal effective doses for tendon adaptation.[00:13:50] The refractory period between optimal tendon loading sessions.[00:16:42] Rapamycin's effects on muscle hypertrophy.[00:18:49] Protocols for tennis elbow rehabilitation.[00:20:28] Why isometrics work better than eccentrics for tendon healing.[00:22:14] Stress shielding and how load distribution affects tendon healing.[00:29:07] The misconception about eccentric loading for tendon injuries and why velocity matters.[00:29:58] Ideal duration for isometric holds (10-30 seconds) based on injury status.[00:33:50] My elbow issues and current rehab approach.[00:36:02] Overcoming vs. yielding isometrics and optimal loading strategies.[00:47:11] Dr. Barr's movement prescription for my tennis elbow.[00:52:18] Loading timing post-surgery and RICE protocol criticism.[00:56:58] Achilles tendon rehabilitation after surgery.[01:00:18] Critique of orthopedic suturing techniques and recommendation for resorbable sutures.[01:04:02] Multiple position isometrics for tennis elbow rehabilitation.[01:07:26] Collagen synthesis, supplementation, and vitamin C timing.[01:12:59] Critique of BPC-157 and other injectable peptides for tendon healing.[01:18:19] Evaluation of orthobiologics' (PRP, prolotherapy, stem cells) effectiveness.[01:21:37] JAK-STAT inhibitor drugs and their effects on tendon growth.[01:25:35] Drugs that increase risk of tendon ruptures (fluoroquinolones, AT-1 receptor drugs).[01:29:33] How estrogen affects tendon stiffness and injury risk in women.[01:32:48] Testosterone's opposite effects on tendon compared to estrogen.[01:35:31] Protein intake recommendations and timing.[01:40:11] Ketogenic diet effects on mitochondrial biogenesis and longevity.[01:41:57] Comparison of ketogenic diet, low protein diet, and rapamycin for longevity.[01:47:19] Inflammation's role in adaptation and when to reduce it.[01:51:17] Timing of ice baths relative to training for optimal recovery.[01:52:33] Parting thoughts.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2025 Ivy Podcast Discovery LLC
